drugset
drugset / Trial / NCT03877536

Antiretroviral Therapy for Acute HIV Infection

NCT03877536 ↗

Withdrawn Henry M. Jackson Foundation for the Advancement of Military Medicine Gilead Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the virologic effect, safety and tolerability of Genvoya® in adults during early acute HIV infection.

Timeline

Start
2019-03-17
Primary completion
2023-09-14
Completion
2025-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject corbiscistat Unknown 150 mg Oral
Subject elvitegravir Small molecule 150 mg Oral
Subject emtricitabine Other / unclassified 200 mg Oral
Subject tenofovir alafenamide Small molecule 10 mg Oral

Indications

HIV infectious disease